$SI

Ahearn Matthew Fraser sold $374K of SI

Ahearn Matthew Fraser (Chief Operating Officer) sold 20,000 shares of SHOULDER INNOVATIONS, INC. (SI) at an average of $18.71 ($18.20–$19.26, $0.37M total) across 3 trades over 2026-06-12 to 2026-06-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Ahearn Matthew Fraser
Published Jun 16, 2026, 8:35 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 16, 2026, 8:36 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$SI
Neutral
medium confidence
Mentioned
$SI
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SINeutralLow
01

Why it matters

The newest information is the disclosed open-market sale by the COO (20,000 shares; weighted avg ~$18.7127; total ~$374K) executed over 2026-06-12 to 2026-06-15 under a 10b5-1 plan.

02

Market read

This is a routine insider sale disclosure; it can slightly influence sentiment but is unlikely to drive a major repricing absent other catalysts.

03

What to watch

Traders may over-weight insider sales; the key is whether there are concurrent disclosures (e.g., earnings, guidance, financing) which are not present here.

Relevance 3/10Novelty 5/10Timing: Filed 2026-06-16; sale executed 2026-06-12 to 2026-06-15.

Background

The article is an SEC Form 4 insider transaction disclosure for Shoulder Innovations, Inc. (SI).

Company-level read

Ticker impact

$SINeutralMedium confidence
Context

Shoulder Innovations COO Matthew Fraser sold 20,000 shares in open-market transactions under a pre-arranged 10b5-1 plan, worth ~$374K.

Expected impact

Likely limited near-term impact; any effect is more sentiment/positioning than a fundamental repricing.

Evidence & confidence

The filing is a routine insider sale with stated 10b5-1 pre-arrangement, reducing interpretive signal versus discretionary selling.

Market effects

No sector-level implications; this is company-specific insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect scheduled liquidity rather than bearish expectations.

Key entities

  • Shoulder Innovations, Inc.

    Company whose insider transaction is disclosed on Form 4.

  • Ahearn Matthew Fraser

    Chief Operating Officer who sold shares in open-market transactions.

  • 10b5-1 plan

    Pre-arranged plan cited as Yes, which can reduce interpretive signal.

Related articles

$SIMed

Shoulder Innovations Q2 Earnings Call Highlights

Shoulder Innovations (NYSE:SI) reported Q2 gross margin of 78.3% versus 76.2% a year earlier, with SG&A rising to $20.1M and R&D to $3.4M. Net loss narrowed to $10.2M. Cash totaled $99M at June 30. The company expects similar gross margins in 2H 2026 and plans FDA submissions for its robotic platform in 2027.

$SIMed

Siemens to acquire EDA software firm Precision Innovations

Siemens said it signed an agreement to acquire privately held US EDA software firm Precision Innovations. Siemens said the deal will add AI-powered chip planning and early design exploration using the OpenROAD framework to help semiconductor teams optimize power, performance and area, reduce iterations, and speed SoC feasibility analysis and time to market.

$SIMedAI 8/10

SHOULDER INNOVATIONS, INC. (SI): Results of Operations and Financial Condition

SHOULDER INNOVATIONS, INC. (SI) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex-991earningsreleaseq22026.htm EX-99.1 Document Exhibit 99.1 Shoulder Innovations Reports Second Quarter 2026 Financial Results and Raises Full Year Outlook Generates First Half 2026 Revenue Growth of 60% Grand Rapids, MI – August 6, 2026 – Shoulder Innovations, Inc. (

$SIMed

Siemens to acquire chip design firm Precision Innovations

Siemens said it agreed to acquire privately held Precision Innovations Inc., an electronic design automation firm. Siemens will add Precision’s AI-powered chip planning tools to its EDA portfolio to help semiconductor teams evaluate design tradeoffs earlier in system-on-a-chip development, aiming to improve power, performance and area outcomes and speed time to production.

$QTTBMedAI 8/10

Top Biotech Gainers: QTTB Sends Strong SIGNAL; AMWL And SI In Focus

Biotech gainers highlighted Q32 Bio (QTTB), up 90.7% to $21.38 after positive Phase 2 SIGNAL-AA results for bempikibart in alopecia areata, and it launched a $200M underwritten stock offering. Agenus (AGEN) rose 82.7% to $6.12 on a planned ~$85M private placement for BOT+BAL Phase 3 ROBBIN1. Other movers: ACTU, GALT, AMWL, SI.